Related Experiment Video
Updated: Aug 25, 2025
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter
Takashi Oyama1, Kensuke Matsuda1, Akira Honda1
1Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Insights
Long-term corticosteroid use in chronic graft-versus-host disease (cGVHD) after stem cell transplant is linked to worse outcomes. Early steroid withdrawal in cGVHD patients is associated with better survival and fewer hospital readmissions.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Chronic graft-versus-host disease (cGVHD) is a significant long-term complication following allogeneic hematopoietic stem cell transplantation.
- The impact of prolonged corticosteroid dependency in steroid-responsive cGVHD remains unclear.
Purpose of the Study:
- To investigate the clinical significance of long-term corticosteroid dependency in patients with steroid-responsive cGVHD.
- To compare outcomes between patients who can discontinue steroids early versus those who remain dependent.
Main Methods:
- Retrospective review of 120 patients with cGVHD treated with systemic steroids between 2007 and 2018.
- Patients were categorized into early withdrawal (EW-cGVHD, steroids tapered within 1 year) and dependent (Dp-cGVHD, prolonged use) groups.
- Outcomes analyzed included overall survival, cGVHD recurrence-free survival, relapse-free survival, and readmission rates.
Main Results:
- The EW-cGVHD group (26 patients) had a significantly higher proportion of men and better performance status compared to the Dp-cGVHD group (55 patients).
- Five-year overall survival (96% vs. 68%) and cGVHD recurrence-free survival (84% vs. 41%) were significantly higher in EW-cGVHD.
- Dp-cGVHD was associated with significantly increased readmission rates (84% vs. 38%), primarily due to cGVHD recurrence or infection.
Conclusions:
- Steroid dependency for over a year in cGVHD is significantly associated with poorer transplant outcomes.
- Early corticosteroid withdrawal in cGVHD patients correlates with improved survival and reduced complications.
- These findings highlight the importance of managing steroid use duration in cGVHD patients post-transplant.
Abstract:
Chronic graft-versus-host disease (cGVHD) is a long-term complication of allogeneic hematopoietic stem cell transplantation. The clinical importance of long-term corticosteroid dependency in steroid-responsive cGVHD is undetermined. We retrospectively reviewed the data of 120 consecutive patients who received systemic steroid therapy for cGVHD between January 2007 and December 2018 at three institutions. Among patients with steroid-responsive cGVHD, those who successfully tapered off corticosteroids within 1 year were defined as the early withdrawal group (EW-cGVHD) and others were defined as the dependent group (Dp-cGVHD). Twenty-six patients were classified as EW-cGVHD and 55 as Dp-cGVHD. The proportion of men was significantly higher and performance status was significantly better in EW-cGVHD. The 5-year overall survival and cGVHD recurrence-free survival rates were significantly higher in EW-cGVHD than Dp-cGVHD (96% vs. 68%, p = 0.017 and 84% vs. 41%, p = 0.002, respectively). While the relapse-free survival rate did not differ significantly (84% vs. 65%, p = 0.15), the proportion of patients requiring readmission, mainly due to cGVHD recurrence or infection, was significantly increased in Dp-cGVHD (38% vs. 84%, p < 0.001). In summary, steroid dependency in cGVHD for more than 1 year was significantly associated with poor transplant outcomes.
More Related Videos
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
10:29Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
Published on: August 29, 2012
Related Concept Videos
01:40Cell-mediated Immune Responses
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids